Corgnac et al. conducted a retrospective study on a cohort of 111 patients with NSCLC, discovering that those with higher pre-IT levels of CD8+ TRM cells, characterized by the CD103+CD49a+CD69+ phenotype, had increased TRM levels during anti-PD-1 treatment. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.